Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070392 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by Immunocore.
- Completed
- Registry status
- Phase 2
- Development phase
- 378
- Enrollment target
- 20
- Study locations
NCT03070392: Completed Phase 2 study of Uveal Melanoma, sponsored by Immunocore.
NCT03070392 is a Phase 2 study of Uveal Melanoma that has completed, run by Immunocore. The registered enrollment target is 378 participants, above the 132-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (186% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03070392, a Phase 2 study of Uveal Melanoma, has completed, sponsored by Immunocore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 378 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
Primary Outcome
Overall survival is defined as the time from randomization to date of death due to any cause.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Ipilimumab
- DRUG Dacarbazine
- BIOLOGICAL IMCgp100
Study Locations (20)
California
- UCLA Medical Center - Los Angeles
- The Angeles Clinic and Research Institute - Los Angeles
- Byers Eye Institute, Stanford University - Palo Alto
- California Pacific Medical Center - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Illinois
- Northwestern University - Chicago
- The University of Chicago Medicine - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Colorado
- University of Colorado - Aurora
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2025-09-17 |
| Phase | Phase 2 |
What the finished NCT03070392 record still lists
NCT03070392 is an interventional study that assigns participants to a tested intervention. The registered 378 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (186% higher).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03070392 names 20 study sites across 13 states, led by California, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT03070392 about?
NCT03070392 is a clinical study titled "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma". To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
What is the current status of trial NCT03070392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 378 participants. The study started on 2017-10-16. Estimated completion is 2025-09-17.
What conditions does trial NCT03070392 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT03070392?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Dacarbazine (DRUG), IMCgp100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03070392?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03070392 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03070392's enrollment target sits among peer trials
378 4th of 29 higher than 26 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI